Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
NCT03139916Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2017
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bavituximab in glioblastoma (GBM), sponsored by Massachusetts General Hospital. Started Sep 2017; status: completed.
02
Drugs
bavituximab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03139916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139916.